Senores Pharmaceuticals Ratios

Senores Pharmaceuticals Ltd Ratios

The Senores Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Senores Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Senores Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Senores Pharmaceuticals Ltd (NSE: SENORES, BSE: 544319) is currently trading at ₹723.90, with a market capitalization of ₹34.61B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Senores Pharmaceuticals Ltd remains a key stock for fundamental analysis using Senores Pharmaceuticals Ltd Ratios.

Senores Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Senores Pharmaceuticals Ltd P/E ratio currently stands at 35.57, making it one of the most tracked metrics in Senores Pharmaceuticals Ltd Ratios.

Historically, the Senores Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 35.57
• 2023: 0
• 2022: 0
• 2021: 0

The rising Senores Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Senores Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.36.

Historical P/B trend:

• 2024: 3.36
• 2023: 0
• 2022: 0
• 2021: 0

Senores Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Senores Pharmaceuticals Ltd P/S ratio currently stands at 5.24, an important part of Senores Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 5.24
• 2023: 0
• 2022: 0
• 2021: 0

The rising Senores Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Senores Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Senores Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Senores Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

The declining Senores Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Senores Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Senores Pharmaceuticals Ltd EV currently stands at ₹20.38B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 20.38B
• 2023: 0
• 2022: 0
• 2021: 0

Senores Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Senores Pharmaceuticals Ltd EV/EBITDA ratio is currently 22.95, a key metric in Senores Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 22.95
• 2023: 0
• 2022: 0
• 2021: 0

Higher Senores Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Senores Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Senores Pharmaceuticals Ltd D/E ratio is currently 0.40, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.40
• 2023: 1.26
• 2022: 1.38
• 2021: 0.40

Senores Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Senores Pharmaceuticals Ltd ROE currently stands at 11.82%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.82
• 2023: 25.19
• 2022: 20.55
• 2021: 0

Senores Pharmaceuticals Ltd maintains stable profitability levels.

Senores Pharmaceuticals Ltd Ratios Analysis Summary

The Senores Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Senores Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Senores Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.